Chemotherapy in gastric cancer & esophageal cancer - Basis, MAGIC trial, FLOT trial, CROSS protocol

Подписаться 26 тыс.

Просмотров 6 тыс.

50% 1

This is the first part of the video on the role of chemotherapy in gastric cancer and esophageal cancer where Dr. Nilesh Lokeshwar focuses on the benefits of chemotherapy in these cancers - adenocarcinoma and explains the outcomes of the FLOT trial, MAGIC trial, and CROSS protocol among few other noteworthy trials.
The discussion begins with a rationale for the need for chemotherapy in gastric cancer and esophageal cancer and then proceeds to critically review the major studies on this topic. So, Do have a look at this video by Edusurg Clinics to understand the role of chemotherapy and radiotherapy, especially in neoadjuvant settings.
COME JOIN US: OUR DETAILS
FACEBOOK: bit.ly/3qaO53R
TWITTER: bit.ly/3legZw7
INSTAGRAM: bit.ly/33mAJaK
E-MAIL ID: learnwithedusurg@gmail.com
WE SUPPORT AND RECOMMEND
Freedom of expression, positivity, and meditation: rdbl.co/3fQMStK
VISIT THE LINK, IF YOU DO TOO.
OUR MOST VIEWED SURGERY VIDEOS
STEP BY STEP LAPAROSCOPIC CHOLECYSTECTOMY: • Laparoscopic cholecyst...
CRITICAL VIEW OF SAFETY IN LAP CHOLECYSTECTOMY: • Critical view of safet...
So. let's have fun...
Do SHARE, SUBSCRIBE, LIKE if you like the approach to this video.
Also, LEAVE TOPICS, SUGGESTIONS in the comments.
Let's make surgery fun, factual, and free...

Опубликовано:

5 июл 2024

Ссылка:

Скачать:

Готовим ссылку...

Добавить в:

Мой плейлист

Посмотреть позже

Комментарии : 8

@khaliddurrani6432 Год назад

I think ECF should still be the gold standard in our part of world esp for an high risk older patient and FLOT for a younger patient ECOG 0-1. Grade 3 toxicity is double with the newerFLOT ,so is the reduced dosage or interruption of treatment. CROSS trial also showed that better response in squamous cell cancers as well as path CR. Not to forget that no amount of chemo/radiation would offset the importance of curative surgery R0 with D2 resection.

@edusurgclinics Год назад

Agree completely. We've also not had good success with FLOT.

@khaliddurrani6432 8 месяцев назад

It’s not the biology of the disease but the biology of the patients and the experience of the center that accounts for unfavorable outcome in our L& M income regions ie Indian subcontinent.

@edusurgclinics 4 месяца назад

It is still the biology of the disease combined with a good team regardless of geographical boundaries that can give a honest outcome - whether good or bad we don't know.